About Us

Our Mission

We believe in the power of innovative medicines to improve human lives by eliminating sensory limitations. Through gene therapy solutions, we aim to initially address the underlying genetic causes of hearing impairment to enhance, or even restore natural communication.
  • Targeted micro-dose delivery of gene therapies, initially focused on large, monogenetic rare disease indications
  • Acquiring clinic-ready asset with initial data read out expected in 2026
  • IND enabling studies for lead genetic hearing loss asset, clinical data 2026 and expected DC for second genetic hearing loss indication 2025
  • Leadership and scientific advisors with deep experience in gene therapy that includes an approval in EU, clinical development, neurology, auditory neuroscience, inner ear biology, and audiology
  • $40M Series A with top-tier investors ARCH Venture Partners and B-Flexion, a Bertarelli Family investment firm

Meet the Team

Leadership
Scientific Advisors
President & CEO
Jodi
Cook, Ph.D.
Chief Development Officer
Shawn
Harriman, Ph.D.
Sr Vice President of Clinical Development and Program Management
Anne Marie
Conway, M.H.A., R.N.
Head of Technical Operations
Anjil
Giri, Ph.D.
Co-Founder
Nilay
Thakar, Ph.D.
Chair of the Board
Steve
Gillis, Ph.D.
Board Member
Giampiero
De Luca, Ph.D.
Co-Founder
David
P. Corey, Ph.D.
40+ years studying inner ear biology; 30 years HHMI
Co-Founder
Casey
Maguire, Ph.D.
20+ years engineering vectors/gene therapies
René
Gifford, Ph.D., CCC-A
25+ years audiology/hearing science; 20 years NIH-funded research
Gregory
Robinson, Ph.D.
30+ years of drug development and gene therapy experience

Stay In

The Know

Blank Form (#3)